SEC Form 4 · accession 0001209191-16-102450
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mariam E Morris
Officer — Chief Financial Officer
Period of report
Feb 24, 2016
Accepted (ET)
Feb 25, 2016 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.01 | Feb 24, 2016 | A | 10,100 | A | — | Feb 24, 2026 | Common Stock | 10,100 | 10,100 | D |
Explanation of responses
- F12,525 of the shares underlying the option shall vest and become exercisable on February 24, 2017; the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter beginning on March 24, 2017, subject to the Reporting Person's continuous service with the Issuer on each such date.